A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis

Males and non-pregnant non-lactating females ≥ 18 years of age providing written informed consent prior to any study-related procedures

Diagnosis of predominantly plaque psoriasis for ≥ 6 months as determined by subject interview and confirmation of diagnosis through physical examination by Investigator

Subject is a candidate for phototherapy or systemic therapy for plaque psoriasis.* *Note: Subjects are required to be candidates for systemic/phototherapy, however no such therapy will be allowed during the study. Please refer to exclusion criteria 3

Moderate to severe plaque psoriasis at Screening and Baseline defined as: • BSA involvement of ≥ 10% • PASI score of ≥ 12 • IGA of at least moderate disease (≥ 3)

Predominantly non-plaque forms of psoriasis like erythrodermic psoriasis, pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new-onset guttate psoriasis

History or presence of uveitis